This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Nitazenes

Authoring team

Nitazenes

Nitazenes are a group of compounds developed in the 1950s as opioid analgesics, but they were never approved to market (1)

  • in the late 1950s, the synthesis of 2-benzylbenzimidazole opioids led to the creation of several compounds now known collectively as nitazenes - although they do not technically meet the current United States Adopted Name (USAN) definition of an "azene" (1)
  • chemical structures are distinct from the typical morphine-like phenanthrene motif and meperidine analogs like fentanyl
  • were intended to be developed as analgesics but they were never approved for any therapeutic purpose

  • a characteristic of nitazenes is their high potency (1,2) - note for comparison fentanyl is 50 x as potent as heroin (2)
    • Metonitazene is 50 x as potent as heroin
    • Protonitazene is 100 x as potent as heroin
    • Isotonitazene is 250 x as potent as heroin
    • Etonitazene is 500 x as potent as heroin

  • several nitazenes, including "designer analogs," have been detected in the illicit drug supply in the last few years
    • have been implicated in overdose mortality, primarily due to their exceptionally high potency in the street drug supply
    • nitazenes are often found mixed with fentanyl or other agents but their presence is not always disclosed to drug buyers, who may not even be familiar with nitazenes
    • in December 2023, the UK National Crime Agency reported 54 deaths in the preceding six months where nitazenes were detected in post-mortem toxicology - although noted that this "is likely the tip of the iceberg" (2)
  • nitazenes can cause fatal respiratory depression (2)

  • in the UK, nitazenes have been detected in substances sold as other opioids, benzodiazepines, and cannabis products (2)

Reference:

  • Pergolizzi J Jr, Raffa R, LeQuang JAK, Breve F, Varrassi G. Old Drugs and New Challenges: A Narrative Review of Nitazenes. Cureus. 2023 Jun 21;15(6):e40736.
  • Holland A et al. Nitazenes - heralding a second wave for the UK drug-related death crisis? Lancet Public Health (January 12th 2024)

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.